Company announces phase III ASCENT study shows Trodelvy (sacituzumab govitecan-hziy) extends overall survival (OS) in brain metastases-negative patients with metastatic triple-negative breast cancer

Patients who had received median of 4 prior anticancer regimens treated with Trodelvy showed statistically significant improvement in OS: median 12.1 months vs. 6.7 months for treatment of choice standard single-agent chemotherapy (HR 0.48; 95% CI, 0.38-0.59; p<0.0001).

SPS commentary:

Trodelvy was approved as a third-line treatment for adult patients with metastatic triple-negative breast cancer under the FDA’s Accelerated Approval Program.

Biospace Inc.